Meta-Analysis: Cardiovascular Events Associated with Nonsteroidal Anti-inflammatory Drugs

• Published in: The American journal of medicine Vol. 119; no. 7; pp. 552 - 559
• Main Authors: Salpeter, Shelley R., Gregor, Peter, Ormiston, Thomas M., Whitlock, Richard, Raina, Parminder, Thabane, Lehana, Topol, Eric J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2006; Elsevier Sequoia S.A
• Subjects: Alzheimer Disease - drug therapy; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Cardiovascular disease; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - etiology; Clinical outcomes; Clinical trials; Cyclooxygenase-2 inhibitors; Humans; Joint Diseases - drug therapy; Meta-analysis; Naproxen - adverse effects; Naproxen - therapeutic use; Non-steroidal anti-inflammatory agents; Nonsteroidal anti-inflammatory drugs; Randomized Controlled Trials as Topic; Risk Factors; Cardiovascular disease; Non-steroidal anti-inflammatory agents; Cyclooxygenase-2 inhibitors; Meta-analysis
• ISSN: 0002-9343; 1555-7162
• DOI: 10.1016/j.amjmed.2005.10.056

We performed a meta-analysis of randomized controlled trials to assess the effect of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) on cardiovascular events in trials of joint disease and Alzheimer’s disease. We performed comprehensive searches of MEDLINE, EMBASE, CINAHL and Cochrane databases from 1966 to July 2005, and references of identified articles and reviews. We included randomized placebo-controlled trials of at least 6 weeks duration that evaluated nonselective NSAIDs in trials of joint disease or Alzheimer’s disease, and reported at least one cardiovascular event or death. The outcome measured was the composite of death, myocardial infarction or cerebrovascular accident, with the pooled results reported as odds ratios (OR). Subgroup analyses evaluated the difference between trials of joint disease and Alzheimer’s disease, and for naproxen and non-naproxen NSAIDs. Pooled data from 13 trials with 7718 participants showed that nonselective NSAIDs had no significant effect on cardiovascular events (OR 1.3; 95% confidence interval [CI], 0.8 to 2.1). No significant effect was seen for joint disease trials (OR 0.6; 95% CI, 0.2 to 1.7) or Alzheimer disease trials (OR 1.6; 95% CI, 0.9 to 2.7). There was no significant difference in results for naproxen and non-naproxen NSAIDs. Nonselective NSAIDs have no significant effect on cardiovascular events or death in trials of joint disease and Alzheimer disease, but a small adverse effect could not be excluded. An indication for risk was present in trials of Alzheimer’s disease but not in joint disease trials. There was no significant adverse or cardioprotective effect of naproxen.